TY  - GEN
AU  - Merdrignac, Lore
AU  - Laniece Delaunay, Charlotte
AU  - Verdasca, Nuno
AU  - Vega-Piris, Lorena
AU  - O'Donnell, Joan
AU  - Sève, Noémie
AU  - Trobajo-Sanmartín, Camino
AU  - Buda, Silke
AU  - Hooiveld, Mariëtte
AU  - Rodrigues, Ana Paula
AU  - Túri, Gergő
AU  - Latorre-Margalef, Neus
AU  - Mlinarić, Ivan
AU  - Lazar, Mihaela
AU  - Maurel, Marine
AU  - Castrillejo, Daniel
AU  - Bennett, Charlene
AU  - Rameix-Welti, Marie-Anne
AU  - Martínez-Baz, Iván
AU  - Dürrwald, Ralf
AU  - Meijer, Adam
AU  - Melo, Aryse
AU  - Oroszi, Beatrix
AU  - Hagey, Tove Samuelsson
AU  - Kurečić Filipović, Sanja
AU  - Dijkstra, Frederika
AU  - Gomez, Verónica
AU  - Bacci, Sabrina
AU  - Kaczmarek, Marlena
AU  - Kissling, Esther
AU  - VEBIS Primary Care Vaccine Effectiveness Group
PY  - 2024
DO  - 10.1111/irv.70009
SN  - 1750-2640
UR  - https://hdl.handle.net/20.500.12105/26417
AB  - We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care...
LA  - eng
PB  - Wiley
KW  - COVID‐19
KW  - SARS‐CoV‐2
KW  - Case–control study
KW  - Multi‐country study
KW  - Primary care
KW  - Test‐negative design
KW  - Vaccine effectiveness
KW  - Aged
KW  - Aged, 80 and over
KW  - COVID-19 Vaccines
KW  - COVID-19
KW  - Case-Control Studies
KW  - Europe
KW  - Female
KW  - Humans
KW  - Male
KW  - Primary Health Care
KW  - SARS-CoV-2
KW  - Vaccination
KW  - Vaccine Efficacy
TI  - Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024
TY  - research article
ER  -